MYC and lymphoma: Accordingly it has been recently demonstrated that tumours bearing high levels of oncogene-induced replicative stress, such as MYC driven aggressive lymphoma mouse models and neuroblastoma, are sensitive to single agent CHK inhibitors [16–18].